皮肌炎皮肤病变临床缓解的相关因素
这项前瞻性队列研究纳入74例成人皮肌炎患者,随访3年,发现38%达到皮肤临床缓解。多因素分析显示年龄增长、合并恶性肿瘤和使用吗替麦考酚酯与缓解显著相关,而抗MDA5抗体阳性者缓解概率更低。
要点
- 38%的皮肌炎患者3年内皮肤病变达到临床缓解。
- 年龄增长、合并恶性肿瘤、使用吗替麦考酚酯与缓解正相关。
- 抗MDA5抗体阳性者皮肤缓解概率显著更低。
核心结论
- 尽管积极系统治疗,皮肌炎皮肤病变临床缓解仍相对少见。
- 抗MDA5抗体阳性患者3年内达到临床缓解的可能性更低。
研究设计与样本
- 前瞻性队列研究,纳入74例成人皮肌炎患者,来自三级学术转诊中心皮肤科门诊。
- 纳入标准为基线CDASI活动度评分≥12且3年内有至少2次间隔≥3个月的CDASI评分。
主要发现
- 74例患者中28例(38%)在3年随访期内达到皮肤临床缓解。
- 抗MDA5抗体阳性患者在时间-事件分析中达到结局标准的概率显著更低。
- 基线皮肤疾病活动度、基线时疾病病程及首次系统治疗前病程与皮肤临床缓解无显著相关。
关键数值与推荐
- 临床缓解通过CDASI评分评估。
- 纳入标准:基线CDASI活动度评分≥12,且3年内至少2次间隔≥3个月的CDASI评分。
临床怎么用
- 吗替麦考酚酯与其他治疗相比可能更有利于皮肤缓解。
- 相当比例皮肌炎患者的标准治疗不足以控制皮肤病变,需关注抗MDA5抗体阳性者。
局限性
- 单中心研究,样本量较小(74例),可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cutaneous disease represents a significant burden for patients with dermatomyositis. However, quantitative estimates of the probability of skin disease remission and clinical factors associated with skin outcomes are lacking. OBJECTIVE: To characterize cutaneous disease course in adult patients with dermatomyositis. DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort study conducted at a dermatology clinic at a tertiary academic referral center. All adult patients with dermatomyositis (age >18 years) seen between May 15, 2007, and October 28, 2016, were eligible. Patients were included in the current analysis if they had a baseline Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) activity score of 12 or higher, and 2 or more CDASI scores separated by 3 months or more within their first 3 years of follow-up. MAIN OUTCOMES AND MEASURES: The percentage of patients who achieved clinical remission of their cutaneous disease as measured by the CDASI over a 3-year follow-up. RESULTS: A total of 74 patients met our inclusion criteria (mean [SD] age at initial CDASI scoring, 54 [13] years; 58 women [78%]), and 28 (38%) achieved clinical remission during our 3-year follow-up period. Increased age (odds ratio [OR], 1.07; 95% CI, 1.02-1.12; P = .01), a dermatomyositis-associated malignancy (OR, 14.46; 95% CI, 2.18-96.07; P = .01), and treatment with mycophenolate mofetil (OR, 6.00; 95% CI, 1.66-21.78; P = .01) were significantly associated with clinical remission of skin disease in multivariable analysis. Patients with anti-melanoma differentiation-associated protein 5 antibodies had a significantly lower probability of meeting outcome criteria in our time-to-event analysis. Baseline cutaneous disease activity, disease duration at baseline, and disease duration before first systemic therapy were not significantly associated with clinical remission of skin disease. CONCLUSIONS AND RELEVANCE: Clinical remission was relatively uncommon in our population despite aggressive systemic therapy, and patients with anti-melanoma differentiation-associated protein 5 antibodies were even less likely to enter clinical remission during a 3-year follow-up period. Although mycophenolate mofetil compared favorably with other treatment options, our data provide evidence that a substantial population of patients with dermatomyositis have skin disease that is not adequately managed with standard-of-care therapies.
引用
- Wolstencroft PW, Chung L, Li S, et al. Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis. JAMA Dermatol. 2018. PMID: 29114741. doi:10.1001/jamadermatol.2017.3758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。